European public assessment reports

  • Email
  • Help

This page allows you to find the European public assessment reports (EPAR) for human medicines published by the European Medicines Agency (EMA).

The EMA publishes an EPAR for every medicine granted a central marketing authorisation by the European Commission following an assessment by the EMA's Committee for Medicinal Products for Human Use (CHMP). EPARs are full scientific assessment reports of medicines authorised at a European Union level. 

Use this search to find information including a public-friendly summary in question-and-answer format and the package leaflet. You can also find information on medicines that have been refused a marketing authorisation or that have been suspended or withdrawn after being approved.

As of October 2016, EMA publishes the clinical data submitted by pharmaceutical companies to support their marketing applications for human medicines under the centralised procedure, allowing the public to better understand the Agency’s decision-making. For more information see clinical data publication.

The Agency does not evaluate all medicines currently in use in Europe. If you cannot find the medicine you need through this search, please visit the website of your national health authority.

More information is available on the Central authorisation procedure and in EPARs: background and context.

Document status

Include:

Browse by letter

Browse by letter for medicines that have a European Public Assessment Report:

Or for other types of content pick from the navigation on the left.

Search by keyword

Search for keyword:

Search by therapeutic area

Browse the database based on therapeutic area:

/

Browse by type

Browse by type:

Download results to spreadsheet
EPAR Search results
Name Active substance Therapeutic area Date of authorisation / refusal Additional monitoring Orphan     Has current safety alert Status
Besponsa

inotuzumab ozogamicin

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2017-06-29           Authorised
Bosulif

bosutinib (as monohydrate)

  2013-03-27           Authorised
Vyndaqel

tafamidis

Amyloidosis 2011-11-16           Authorised
Kolbam

cholic acid

Metabolism, Inborn Errors 2015-11-20           Authorised
Esbriet

pirfenidone

Idiopathic Pulmonary Fibrosis 2011-02-28           Authorised
Gazyvaro

obinutuzumab

Leukemia, Lymphocytic, Chronic, B-Cell 2014-07-23           Authorised
Natpar

parathyroid hormone

Hypoparathyroidism 2017-04-24           Authorised
Revestive

teduglutide

Malabsorption Syndromes 2012-08-30           Authorised
Alprolix

eftrenonacog alfa

Hemophilia B 2016-05-12           Authorised
Adcetris

brentuximab vedotin

Hodgkin Disease Lymphoma, Non-Hodgkin 2012-10-25           Authorised
Ninlaro

ixazomib citrate

Multiple Myeloma 2016-11-21           Authorised
Kalydeco

ivacaftor

Cystic Fibrosis 2012-07-23           Authorised
Glybera

alipogene tiparvovec

Hyperlipoproteinemia Type I 2012-10-25           Withdrawn